Nuvo Pharmaceuticals Inc (NRI)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014330)
◆英語タイトル:Nuvo Pharmaceuticals Inc (NRI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014330
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:56
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Nuvo Pharmaceuticals Inc (Nuvo), formerly known as Nuvo Research Inc is a drug company that offers topical pain products and technologies. The company’s product portfolio includes pennsaid, pennsaid 2%, and heated lidocaine and tetracaine patches. Its products deliver drugs topically into and through the skin to the specific site of activity. Nuvo’s pennsaid and pennsaid 2%, transdermal drug carriers, used for the treatment of osteoarthritis of the knee. heated lidocaine/tetracaine patch, a topical patch, acts as a local analgesia. The company markets its products through a network of distributors in Canada, European Union Zone and the US. Its manufacturing facility is located in Varennes, Motreal, Quebec, Canada. Nuvo Pharmaceuticals is headquartered in Mississauga, Ontario, Canada.

Nuvo Pharmaceuticals Inc (NRI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Nuvo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Nuvo Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Nuvo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Nuvo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Nuvo Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Nuvo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Nuvo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Nuvo Research Reacquires Pennsaid Rights from Paladin Labs 13
Partnerships 14
Nuvo Research Enters Into Co-Development Agreement With Ferndale Labs And Contract Research Organization 14
Nuvo Research Enters Into Distribution Agreement With NovaMedica For Pennsaid 15
Licensing Agreements 16
Sayre Therapeutics Enters into Licensing Agreement with Nuvo Pharma 16
Nuvo Research Enters into Licensing Agreement with Galderma Pharma for Pliaglis 17
Nuvo Research Enters Into Licensing Agreement With Paladin Labs For Synera 18
Equity Offering 19
Nuvo Research Completes Private Placement Of Units For US$2.8 Million 19
Asset Transactions 20
Horizon Pharma Acquires US Rights to Pennsaid 2% from Nuvo Research for USD45 Million 20
Galen Acquires US Rights For Synera From Nuvo Research For USD14.5 Million 22
Tioga Acquires HTE Formulation Patents from Nuvo Research 23
Acquisition 24
Nuvo Research Acquires 40% Stake in Nuvo Research AG 24
Nuvo Research Acquires ZARS Pharma 25
Nuvo Pharmaceuticals Inc – Key Competitors 27
Nuvo Pharmaceuticals Inc – Key Employees 28
Nuvo Pharmaceuticals Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Nov 01, 2017: Nuvo Pharmaceuticals Announces 2017 Third Quarter Results 30
Aug 09, 2017: Nuvo Pharmaceuticals Announces 2017 Second Quarter Results 33
May 10, 2017: Nuvo Pharmaceuticals Announces 2017 First Quarter Results 36
Mar 01, 2017: Nuvo Pharmaceuticals Announces 2016 Year-End and Fourth Quarter Results 38
Nov 10, 2016: Nuvo Pharmaceuticals Announces 2016 Third Quarter Results 41
Aug 10, 2016: Nuvo Pharmaceuticals Announces 2016 Second Quarter Results 44
May 11, 2016: Nuvo Pharmaceutical Announces 2016 First Quarter Results 46
Feb 17, 2016: Nuvo Research Announces 2015 Fourth Quarter & Year-End Results 48
Jan 21, 2016: Nuvo Research Provides Estimated Revenue for the 2015 Fourth Quarter and Year End 50
Corporate Communications 51
Nov 16, 2016: Nuvo Pharmaceuticals appoints new president 51
Nov 16, 2016: Nuvo Pharmaceuticals Appoints Jesse Ledger as President 52
Sep 01, 2016: Nuvo Pharmaceuticals Appoints New Chief Financial Officer 53
Legal and Regulatory 54
Feb 24, 2016: Nuvo Research Obtains Final Court Order Approving Reorganization into Two Publicly-Traded Companies 54
Other Significant Developments 55
Mar 01, 2016: Nuvo Research Completes Reorganization into Two Publicly Traded Companies 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
Nuvo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Nuvo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Nuvo Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Nuvo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Nuvo Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Nuvo Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Nuvo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Nuvo Research Reacquires Pennsaid Rights from Paladin Labs 13
Nuvo Research Enters Into Co-Development Agreement With Ferndale Labs And Contract Research Organization 14
Nuvo Research Enters Into Distribution Agreement With NovaMedica For Pennsaid 15
Sayre Therapeutics Enters into Licensing Agreement with Nuvo Pharma 16
Nuvo Research Enters into Licensing Agreement with Galderma Pharma for Pliaglis 17
Nuvo Research Enters Into Licensing Agreement With Paladin Labs For Synera 18
Nuvo Research Completes Private Placement Of Units For US$2.8 Million 19
Horizon Pharma Acquires US Rights to Pennsaid 2% from Nuvo Research for USD45 Million 20
Galen Acquires US Rights For Synera From Nuvo Research For USD14.5 Million 22
Tioga Acquires HTE Formulation Patents from Nuvo Research 23
Nuvo Research Acquires 40% Stake in Nuvo Research AG 24
Nuvo Research Acquires ZARS Pharma 25
Nuvo Pharmaceuticals Inc, Key Competitors 27
Nuvo Pharmaceuticals Inc, Key Employees 28
Nuvo Pharmaceuticals Inc, Subsidiaries 29

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Nuvo Pharmaceuticals Inc (NRI)-製薬・医療分野:企業M&A・提携分析(Nuvo Pharmaceuticals Inc (NRI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆